Claims for Patent: 8,025,634

Summary for Patent: 8,025,634

Title:	Method and system for controlled infusion of therapeutic substances
Abstract:	Programmable infusion systems and method for controlled infusion of diagnostic or therapeutic substances (e.g., drugs, biologics, fluids, cell preparations, etc.) into the bodies of human or animal subjects.
Inventor(s):	Moubayed; Ahmad-Maher (Mission Viejo, CA), Hyman; Oscar E. (Poulsbo, WA), White; David N. (San Juan Capistrano, CA), Wilson; Larry L. (Poway, CA), Stevenson; John W. (Carlsbad, CA), Moubayed; Jay G. (Aliso Viejo, CA), Thomas; Linda (Laguna Niguel, CA)
Assignee:	Baxter International Inc. (Deerfield, IL) Baxter Healthcare S.A. (Glattpark (Opfikon), CH)
Application Number:	11/523,794
Patent Claims:	1. A system for administering a substance to a subject, said system comprising: a pump including a housing; a controller that is in communication with the pump and issues control signals to the pump; a user interface external to the pump housing and configured to present queries to the subject regarding whether the subject may be experiencing an adverse reaction to the substance and to receive responses to the queries; a plurality of vital signs monitors; a substance administering conduit for delivering the substance to the subject's body; a storage medium that contains at least one controller-accessible database selected from the group of databases consisting of: a) a substance protocol database, b) a subject protocol database, c) a therapy-type protocol database, d) a substance reference library database, e) a system configuration database, f) a history database and g) combinations thereof, and wherein the controller is programmed to operate with the user interface and the plurality of vital sign monitors to: (i) receive at least one vital sign signal from the plurality of vital sign monitors, (ii) determine, in response to the receipt of the vital sign signal, whether the subject may be experiencing an adverse reaction to the substance, (iii) cause the user interface to present at least one of said queries to the subject when the determination in response to (ii) is that the subject may be experiencing an adverse reaction to the substance, and (iv) monitor a response by the subject to the at least one presented query to determine whether the subject is suffering an adverse reaction to the substance. 2. A system according to claim 1 wherein said at least one controller-accessible database comprises a substance protocol database. 3. A system according to claim 2 wherein the substance protocol database contains infusion protocol information for one or more substances and wherein the system further comprises an operator interface that may be used to select a particular substance within the substance protocol database. 4. A system according to claim 3 wherein the infusion protocol information includes i) a maximum permissible infusion volume, ii) a maximum permissible infusion rate, iii) a substance concentration limit, iv) contraindications and iv) any known substance to substance interactions, for each substance included in the substance protocol database. 5. A system according to claim 2 wherein said at least one controller-access database further comprises a substance reference library database including an adverse reaction symptom list. 6. A system according to claim 1, wherein the plurality of vital sign monitors are operably connected to the controller, said plurality of vital sign monitors selected from the group consisting of a blood pressure monitor, a temperature monitor, a pulse rate monitor and a monitor for oxygen saturation level. 7. A system according to claim 5 wherein the substance reference library is separate from the substance protocol database. 8. A system according to claim 5 wherein the substance protocol database includes an identifier for each substance contained therein, said identifier being useable by the controller to access the substance information found in the substance reference library database. 9. A system according to claim 1 wherein at least one controller-accessible database comprises a system configuration database that contains configurable parameters for the system. 10. A system according to claim 1, wherein the at least one controller accessible database comprises a system configuration database that contains infusion rate limits and wherein the system is further adapted to allow a caregiver or an operator to change said infusion rate limits. 11. A system according to claim 1, wherein the controller is configured for stopping or modifying administration of the substance if the vital sign monitors indicate the subject is suffering an adverse reaction. 12. A system according to claim 1 wherein the system configuration database contains at least one set of configuration parameters comprising: a name, an indication of either enable or disable for a plurality of therapeutic modes, and limits for one or more operating parameters for each therapeutic mode that is enabled. 13. A system according to claim 2 wherein the controller is adapted to issue control signals to the pump based on information accessed from the system configuration database. 14. A system according to claim 1 wherein said at least one controller-accessible database comprises a subject protocol database containing infusion protocol information for one or more subjects. 15. A system according to claim 14 wherein said at least one controller accessible database further comprises a substance reference library database. 16. A system according to claim 15 wherein the substance reference library database is separate from the subject protocol database. 17. A system according to claim 15 wherein the subject protocol database includes an identifier for a substance, said identifier being useable by the controller to access information found in the substance reference library database. 18. A system according to claim 14 wherein the system further comprises a user interface which allows the user to select a particular subject for whom information is to be retrieved from the subject protocol database. 19. A system according to claim 14 wherein the subject protocol database includes information for each subject comprising: name, address, gender, age, weight, allergies and special notes. 20. A system according to claim 14 wherein the subject protocol database information includes at least one prescribed infusion protocol for each subject contained therein. 21. A system according to claim 20 wherein the controller is adapted to access a prescribed infusion protocol for a selected subject and to issue control signals to the pump in accordance with that prescribed infusion protocol. 22. A system according to claim 1 wherein said at least one controller-accessible database comprises a substance reference library database. 23. A system according to claim 22 wherein the substance reference library database includes information for one or more substances, said information comprising: maximum permissible infusion volume, maximum permissible infusion rate, substance concentration limits, contraindications, and substance to substance interactions. 24. A system according to claim 11, wherein after administration is stopped, the controller is configured to suggest a lower infusion rate of the substance to the subject. 25. A system according to claim 24 wherein the controller is adapted to access a recommended infusion protocol for a selected substance and to issue control signals to the pump in accordance with that recommended infusion protocol. 26. A system according to claim 1 which includes an infusion protocol database operable with the controller to: i) if the vital signs of the subject indicate an adverse reaction, stop administering the substance; and ii) if the vital signs of the subject indicate no adverse reaction, continue to administer the substance through the conduit in accordance with the infusion protocol. 27. A system according to claim 26 wherein the infusion protocol database contains infusion protocol information for one or more therapy types selected from the group of: continuous infusion therapy, intermittent infusion therapy, intravenous immune globulin therapy and Infliximab therapy. 28. A system according to claim 26 wherein the infusion protocol database contains infusion protocol information for intravenous immune globulin therapy, said infusion protocol information comprising one or more items of information selected from: volume to be infused, minimum infusion time, maximum infusion time, beginning infusion rate, maximum infusion rate, rate change increment, and number of rate change steps wherein each rate change step comprises an initial rate, a terminal rate, a total step duration, and a change of rate duration between steps. 29. A system according to claim 26 wherein the infusion protocol database contains infusion protocol information for Infliximab therapy, said infusion protocol information comprising one or more items of information selected from: volume to be infused and a plurality of infusion steps wherein each step is defined by infusion rate, infusion time and change of rate duration from the previous step. 30. A system according to claim 26 wherein the controller is adapted to access infusion protocol information for a selected therapy type and to issue control signals to the pump in accordance with that infusion protocol information. 31. A system according to claim 1 wherein the at least one controller-accessible database comprises a history database. 32. A system according to claim 31 wherein the controller records events and operator interactions into the history database. 33. A system according to claim 31 wherein the controller displays some or all of the contents of the history database in readable form. 34. A system according to claim 31 further comprising a printer in communication with the controller, wherein the controller causes some or all of the contents of the history database to be printed by the printer. 35. A system according to claim 1 wherein the apparatus presenting a query is operative to query the subject regarding feelings, sensations, symptoms or other bodily responses experienced by the subject during or after an infusion. 36. A system according to claim 35 wherein the apparatus for presenting a query is operative to query the subject regarding at least one feeling, sensation, symptom or other bodily response selected from the group consisting of: nausea, vertigo, sensations of smell, sensations of taste, confusion, memory, alertness, sleepiness, drowsiness, perception of being warm, perception of being cold, shivering, pain, non-volitional muscle contractions, a symptom of an overdose of the substance, a symptom of an under-dose of the substance, a symptom of the substance being infused too rapidly, a symptom of the substance being infused too slowly, a symptom indicating that the substance is having a desired effect and a symptom indicating that the substance is having an undesired effect. 37. A system according to claim 1 wherein the controller is programmed to determine whether or not the subject's response indicates that the subject is experiencing an adverse reaction. 38. A system according to claim 37 wherein the controller is programmed to issue signals to stop the infusion or to modify the rate of infusion, if it is determined that the subject's response indicates that the subject is experiencing an adverse reaction. 39. A system according to claim 37 wherein the controller categorizes the subject's response into a category selected from: a) no adverse reaction, b) mild adverse reaction, c) moderate adverse reaction or d) severe adverse reaction. 40. A system according to claim 39 wherein the controller is programmed to issue signals to stop the infusion or to modify the rate of infusion depending on the category in which the subject's response is categorized. 41. A system according to claim 37 wherein, if an adverse reaction is determined, the controller generates a message to the operator indicating the occurrence of the adverse reaction. 42. A system according to claim 37 wherein said at least one database includes a history database and wherein, if an adverse reaction is determined, the controller causes a record of the adverse reaction to be stored in the history database. 43. A system according to claim 1 wherein the plurality of vital sign monitors are configured to monitor one or more physiologic variables of the subject. 44. A system according to claim 43 wherein said plurality of vital sign monitors are operative to measure one or more variables selected from the group consisting of: heart rate, blood pressure, body temperature, respiratory rate, oxygen saturation, carbon monoxide saturation, profusion index, methemoglobinemia, skin response and airway resistance. 45. A system according to claim 43 wherein the plurality of vital sign monitors are configured for transmitting signals to the controller and wherein the controller is programmed to use the signals to determine whether or not the monitored physiologic variable(s) indicate that the subject is experiencing an adverse reaction. 46. A system according to claim 45 wherein the controller is programmed to issue control signals to stop the infusion or to modify the rate of infusion, if it is determined that the subject is experiencing an adverse reaction. 47. A system according to claim 46 wherein the controller is programmed to use the signals to categorize the monitored physiologic variable(s) into a category selected from the group consisting of: a) no adverse reaction, b) mild adverse reaction, c) moderate adverse reaction and d) severe adverse reaction. 48. A system according to claim 47 wherein the controller is programmed to issue signals to stop the infusion or to modify the rate of infusion depending on the category in which the subject's response is categorized. 49. A system according to claim 45 wherein, if an adverse reaction is determined, the controller is configured to generate a message to an operator indicating the occurrence of the adverse reaction. 50. A system according to claim 45 wherein at least one database includes a history database and wherein, if an adverse reaction is determined, the controller is configured to cause a record of the adverse reaction to be stored in the history database. 51. A system according to claim 1 further comprising a data entry device connected to the controller, the data entry device configured to store the record of the adverse reaction to the history database. 52. A system according to claim 1 further comprising a substance administering conduit through which the substance is delivered to the subject. 53. A system according to claim 52 wherein the conduit comprises an intravenous line. 54. A system according to claim 52 further comprising a vessel containing a quantity of the substance and connected to the pump such that the pump may deliver the substance from the vessel through the substance administration conduit. 55. A system according to claim 54 wherein the substance is selected from the group consisting of: a drug, a biologic, a gene therapy preparation, a diagnostic agent, a fluid, a protein, and an immunotherapeutic agent. 56. A system according to claim 54 wherein the substance comprises immune globulin. 57. A system according to claim 54 wherein the substance comprises lnfliximab. 58. A system according to claim 54 wherein the substance comprises blood components for treatment of autoimmune diseases. 59. A system according to claim 1 wherein the pump comprises a peristaltic pump. 60. A system according to claim 59 wherein the pump comprises an axial peristaltic pump. 61. A system according to claim 59 wherein the pump comprises a rotary axial peristaltic pump. 62. A system according to claim 61 wherein the rotary axial peristaltic pump comprises: a platen having a platen surface; a tube positioned adjacent to the platen surface; a cam that rotates about a rotational axis, said cam having a cam surface that is spaced apart from the platen surface; and a plurality of fingers, each finger having a longitudinal axis that is substantially parallel to the rotational axis of the cam, said fingers being in engagement with the cam surface such that, as the cam rotates about the rotational axis, the fingers will move axially back and forth, sequentially compressing the tube against the platen surface and thereby causing peristaltic movement of fluid through the tube. 63. A system according to claim 1 further comprising a communications module configured to provide communication between the controller and one or more external networks or electronic devices. 64. A system according to claim 63 wherein the communications module is configured to communicate information selected from the group consisting of: configuration records, a configuration database, subject records, a subject database, substance records, a substance database, infusion protocol records and an infusion protocol database. 65. A system according to claim 63 wherein the communications module is configured to communicate information that is used for programming, modifying, and executing an infusion protocol. 66. A system according to claim 65 wherein the communications module is configured for communicating information that is used for changing the rate of, or stopping, the infusion protocol. 67. A system according to claim 63 wherein the communications module includes at least one interface to one or more of the plurality of vital sign monitors that monitor one or more vital signs or other physiologic variables of the patient. 68. A system according to claim 63 wherein the communications module includes a memory device accessible by the controller for reading and writing of information. 69. A system according to claim 63 wherein the communications module includes an interface to a memory device that is accessible by the controller for reading and writing of information. 70. A system according to claim 63 wherein the communications module comprises a hard wired connection to an external network. 71. A system according to claim 63 wherein the communications module comprises a wireless connection to an external network.

Details for Patent 8,025,634

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2039-03-29
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	05/21/2004		2039-03-29
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	03/26/2007		2039-03-29
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	07/11/2014		2039-03-29